Free Trial

Swedbank AB Has $40.41 Million Stake in Stryker Co. (NYSE:SYK)

Stryker logo with Medical background

Swedbank AB grew its stake in Stryker Co. (NYSE:SYK - Free Report) by 119.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 112,241 shares of the medical technology company's stock after buying an additional 61,171 shares during the quarter. Swedbank AB's holdings in Stryker were worth $40,412,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in SYK. Parnassus Investments LLC bought a new position in Stryker during the 3rd quarter worth about $762,798,000. International Assets Investment Management LLC grew its holdings in shares of Stryker by 66,967.5% during the third quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company's stock worth $308,433,000 after buying an additional 852,496 shares in the last quarter. RTW Investments LP acquired a new stake in Stryker in the 3rd quarter valued at approximately $143,392,000. State Street Corp lifted its stake in Stryker by 2.2% in the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock valued at $5,279,788,000 after acquiring an additional 316,404 shares in the last quarter. Finally, FMR LLC boosted its position in Stryker by 3.0% during the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock worth $2,639,725,000 after acquiring an additional 215,782 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Performance

NYSE SYK traded up $0.47 on Friday, reaching $390.90. The stock had a trading volume of 1,549,097 shares, compared to its average volume of 1,439,048. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a fifty day moving average of $376.68 and a two-hundred day moving average of $363.02. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a market cap of $149.02 billion, a P/E ratio of 50.37, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same period in the previous year, the business posted $3.46 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 13.53 EPS for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were issued a $0.84 dividend. The ex-dividend date of this dividend was Tuesday, December 31st. This is a boost from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker's payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SYK. Barclays lifted their price objective on shares of Stryker from $402.00 to $418.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. Morgan Stanley upgraded shares of Stryker from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Needham & Company LLC reiterated a "buy" rating and set a $442.00 target price on shares of Stryker in a report on Wednesday. Piper Sandler reaffirmed an "overweight" rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Finally, Evercore ISI raised their target price on shares of Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $419.37.

Get Our Latest Report on Stryker

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines